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Background: Stratified medicine seeks to identify patients most likely to
respond to treatment. Individual participant data (IPD) network meta-analysis
(NMA) models have greater power than individual trials to identify
treatment-covariate interactions (TCIs). Treatment-covariate interactions con-
tain “within” and “across” trial interactions, where the across-trial interaction
is more susceptible to confounding and ecological bias.
Methods:We considered a network of IPD from 37 trials (5922 patients) for cer-
vical cancer (2394 events), where previous research identified disease stage as
a potential interaction covariate. We compare 2 models for NMA with TCIs: (1)
2 effects separating within- and across-trial interactions and (2) a single effect
combining within- and across-trial interactions. We argue for a visual assess-
ment of consistency of within- and across-trial interactions and consider more
detailed aspects of interaction modelling, eg, common vs trial-specific effects
of the covariate. This leads us to propose a practical framework for IPD NMA
with TCIs.
Results: Following our framework, we found no evidence in the cervical cancer
network for a treatment-stage interaction on the basis of the within-trial inter-
action. The NMA provided additional power for an across-trial interaction over
and above the pairwise evidence. Following our proposed framework, we found
that the within- and across-trial interactions should not be combined.
Conclusion: Across-trial interactions are susceptible to confounding and eco-
logical bias. It is important to separate the sources of evidence to check their
consistency and identify which sources of evidence are driving the conclusion.
Our framework provides practical guidance for researchers, reducing the risk of
unduly optimistic interpretation of TCIs.
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1 BACKGROUND
1.1 Introduction
Stratified medicine seeks to identify patients most likely
to respond to treatment. However, individual trials are
rarely powered to detect interactions between treatment
effects and participant characteristics. Meta-analysis (MA)
models potentially have greater power to identify such
treatment-covariate interactions (TCIs), particularly when
individual participant data (IPD) are available. One of the
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big advantages of IPD MA over aggregate data MA is the
greater power that it affords for investigating treatment
and patient-level covariate interactions.1-4 To explore how
the treatment effect may vary in relation to a patient-level
covariate, a TCI can be fitted.5,6 The power to detect a TCI
will depend on the distribution of the covariatewithin each
study.7
Pairwise IPD MA of a TCI often results in 2 sources
of information—so-called within-trial (at the individ-
ual patient level) and across-trial(at the trial level)
interactions—where the across-trial interaction is partic-
ularly susceptible to confounding and ecological bias as it
is based on observational associations.1,2,6-10 The same is
true of IPD network MA(NMA); therefore, it is important
that the within- and across-trial interaction estimates are
reviewed separately, before deciding whether to combine
them. We reiterate that confounding from unmeasured
covariates (eg, differences in baseline disease risk) can
affect both within- and across-trial interactions.11 How-
ever, within-trial effects are less susceptible because
of the protection provided by the trial randomisation.
Ecological bias arises if across-trial information, which
uses trial average covariate values, is used to draw con-
clusions about individuals.7,12-14 However, if interest
lies in the population level effect and it is interpreted
correctly as a population effect (and not an individual
effect), then (by definition) there cannot be ecologi-
cal bias. In some instances, it may be the case that
the across-trial interaction (eg, the mean effect for a
patient aged 50) truly differs from the within-trial inter-
action (eg, the effect for an individual patient aged
50).7 Separating out within- and across-trial interactions
may change the conclusions drawn from combining
within- and across-trial interactions. For example, an
IPD MA comparing 2 antiepileptic drugs as monother-
apy for controlling seizures originally combined the
within- and across-trial interactions and identified an
interaction between treatment and age.15 However,
a recent reanalysis separating out the within- and
across-trial interactions no longer indicated an inter-
action between treatment and age on the basis of the
within-trial interaction only.6
Individual participant data MA models separating out
within- and across-trial interactions were first devel-
oped for continuous outcomes8 and later applied to
time-to-event outcomes.16 In the IPDNMA setting, models
separating out within- and across-trial interactions
have been proposed for dichotomous outcomes5 and
time-to-event outcomes using the Cox regression model.6
In this paper, we show how to separate out the within-
and across-trial interactions in the IPD NMA setting
for time-to-event outcomes using the Royston-Parmar
model.
A key assumption of NMA is consistency between the
direct and indirect evidence.17,18 The inclusion of TCIs in
a NMA model offers one of many ways for exploring and
understanding inconsistency.5,19-21 With the presence of
TCIs in a NMAmodel, the consistency assumptionmay be
violated if one ormore of the true treatment effects is mod-
ified by a covariate and included trials differ with respect
to the covariate.5 Furthermore, when we include TCIs in
a NMA model, we assume that the treatment effects esti-
mated at the covariate value of 0 are consistent and that
the regression coefficients for the TCI parameters are also
consistent.22 Therefore, it is important to assess the con-
sistency assumption either at each level of the covariate
(for categorical covariates) or across a range of values (for
continuous covariates).22
There are 3 different ways to model TCI effects: com-
mon, independent, or exchangeable.19 Common effects
assume that the regression coefficients are the same for
all TCIs so that the TCI effect is the same for each treat-
ment compared with the control. Independent effects
assume that all TCIs are different for each treatment ver-
sus the control so that a separate regression coefficient for
each TCI is included in the model. Exchangeable effects
assume that all TCIs are different from each other but
similar enough that they can be sampled from a com-
mon distribution. For IPD MA, and as we show by exten-
sion in IPD NMA, there are 3 possible ways of analysing
TCIs: using the across-trial interaction only, using the
within-trial interaction only, and combining the two.23 We
now describe 3 approaches for IPD MA with TCI before
considering the NMA setting.
In one commonly used approach for interactions
in MA (which can be shown to combine within- and
across-trial interactions), specifically for categorical
covariates, the treatment effect is calculated within each
trial for each level of the covariate. The treatment effects
for each level of the covariate are combined across all
trials, using standard MA techniques, resulting in an
overall effect for each level of the covariate, which are
then compared with each other.8,16,23 Any trials where all
patients have the same covariate value will not contribute
to the within-trial interaction but can contribute to the
across-trial interaction. This is a common approach used
in IPD MA. However, the within-trial interaction can be
exaggerated or masked by the across-trial interaction,
which is at risk of ecological bias. Therefore, this approach
is also at risk of ecological bias.8,16,23
An analysis using the across-trial interaction only con-
siders how the treatment effect varies across trials in rela-
tion to the trial mean value of the covariate and fails
to use the patient-level information.24 This requires the
assumption of no unmeasured confounding between the
outcome and the covariate, and that there is no ecological
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bias.8,9,23 Unfortunately, it is typically not possible to iden-
tify such confounders as baseline data often vary across
trials. Therefore, it is often not possible to test whether the
inclusion of the across-trial interaction will induce bias.
An analysis using the within-trial interaction only more
closely parallels the underlying principles of MA. Esti-
mates of the TCI effect are calculated within each trial
and then pooled together using MA methods.7,8,16 Any
trials where all patients have the same covariate value
will not contribute to this analysis as they do not provide
any within-trial interactions.7,8,23 Recommendations on
the presentation and analysis of TCIs using this approach
are proposed by Fisher et al.23 A key aim of this paper is to
show how these recommendations can be brought to bear
in NMA.
In the pairwise MA case, it is clear that within-trial
interactions are the most clinically relevant estimates,
as they are free from ecological bias.1,5,6,8,23 In the
NMA case, more research is needed to explore how
the consistency assumptions of the network applied to
within-trial interactions (as in our model) can help
to improve their precision. Nevertheless, the frame-
work described here explicitly separates the within- and
across-trial interactions throughout the network and
hence guarantees that an unbiased estimate of the
within-trial interaction is obtained. The methods pro-
posed here are applicable to both continuous and cat-
egorical covariates. Specifically, in this paper, we illus-
trate how the within- and across-trial interactions can
be separated for time-to-event outcomes modelled using
the IPD Royston-Parmar NMA model, and we propose
a framework for conducting NMA with TCIs, showing
how to fit models that separate out the within- and
across-trial interactions. We then illustrate our framework
by applying it to a cervical cancer network.
1.2 Why do we need a framework?
Fitting a NMA with TCIs is often a more complex pro-
cess than researchers anticipate. There are a number of
additional important decisions that need to be taken,
beyond those that need to be considered in a MA. These
include the parameterisation and consistency of covari-
ate and interaction effects. An added complication, fre-
quently encountered in practice, is how to handle missing
patient-level covariate data.
When it comes to reporting a NMA with TCIs, the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses based on IPD guidelines recommend pre-
specification of whether the across-trial interaction is to be
combinedwith thewithin-trial interaction.4,25 Therefore, it
is important that authors are aware of the potential impli-
cations of combining within- and across-trial interactions.
By proposing a framework for conducting NMA with
TCIs, we aim to equip researchers with the knowledge
and tools for successfully fitting an appropriate NMA
with TCIs.
In Section 2, we discuss issues to consider before con-
ducting NMA with TCIs, outline a 9-step framework for
1-stage IPD NMA with TCIs, provide guidance on imple-
menting the framework, and introduce a cervical cancer
dataset. In Section 3, we present the results of applying the
framework to the cervical cancer network. In Section 4, we
discuss the framework before drawing some conclusions
in Section 5.
2 METHODS
2.1 Issues to consider
2.1.1 Preliminary analysis
A NMA often starts with a systematic review being con-
ducted to identify all treatments and trials to be considered
in the network. As part of the review and in discussion
with appropriate clinicians, discussion of any covariates
that could be included in a NMA with TCIs should take
place before any models are fitted. Such models require
a number of considerations, and preliminary analysis of
the data can help inform the decision of which model
to fit.
2.1.2 Commonmain effect vs trial-level
main effect of covariate
A patient-level covariate can be fitted as a common effect
or a trial-level effect.26 A common effect pools the effect of
the covariate across all trials. A fixed-trial effect results in
a separate estimate of the effect of the covariate for each
trial and does not provide an overall effect for the covari-
ate. A random trial effect of a covariate allows the effect
of the covariate to differ in each trial assuming that the
coefficients for each trial come from a common (typically
normal) distribution.
We encourage the use of a trial-level effect, either fixed
or random. If a common effect of a covariate is used when
a trial-level effect would be more appropriate, this can
result in a poorly fitting model, which could affect conver-
gence, suppress the differences between trials, and affect
the treatment effect estimates. Assuming a common effect
of a covariate is generally not appropriate when the distri-
bution of the covariate varies between trials or in a network
where trials vary in size, because it is known that smaller
studies can give more extreme parameter estimates.27
A hypothesis test to check the effect of the covariate
in each trial should be conducted before assuming a
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common effect, as this choice is likely to critically impact
the estimate of the TCI.
2.1.3 Parameterisation of within- and
across-trial interactions
ATCI can be included inMAmodels in 2 ways: firstly, as a
single effect that combineswithin- and across-trial interac-
tions and secondly, as 2 effects that separate out thewithin-
and across-trial interactions.8,16 Wenowdescribe how to do
this in the NMA setting using the Royston-Parmar model
for time-to-event data.
Consider the 1-step fixed treatment effect
(FTE) Royston-Parmar NMA model for a network of
q + 1 treatments.28By including a fixed-trial effect of a
patient-level covariate zij, the log cumulative hazard for
patient i from trial j can be modelled as
ln{H𝑗(t|xi𝑗)} = s𝑗 (ln(t)) + 𝛽1trt1i𝑗 + · · · + 𝛽qtrtqi𝑗 + 𝛼𝑗zi𝑗 ,
(1)
where s𝑗 (ln(t)) is the restricted cubic spline for trial j,
trt1ij, … , trtqij are the treatment indicators with corre-
sponding coefficients 𝛽1, … , 𝛽q, and 𝛼j is the effect of the
patient-level covariate zij for trial j.
Adding a common TCI to (1), which separates the
within- and across-trial interactions, results in
ln{H𝑗(t|xi𝑗)} = s𝑗 (ln(t)) + 𝛽1trt1i𝑗 + · · ·
+ 𝛽q trtqi𝑗 + 𝛼𝑗(zi𝑗 − z̄𝑗)
+ 𝛿A1trt1i𝑗(zi𝑗 − z̄𝑗) + · · ·
+ 𝛿Aq trtqi𝑗(zi𝑗 − z̄𝑗)
+ 𝛿B1trt1i𝑗 z̄𝑗 + · · · + 𝛿Bqtrtqi𝑗 z̄𝑗 ,
(2)
where the covariate zij is fitted as a fixed trial-level effect
with coefficient 𝛼j for trial j and z̄𝑗 is the mean value of zij
for trial j. The within-trial interaction is represented by the
𝛿A1, … , 𝛿Aq parameters while the across-trial interaction
is represented by the 𝛿B1, … , 𝛿Bq parameters. The differ-
ence 𝛿Bk − 𝛿Ak quantifies the amount of ecological bias for
interaction k.16
Adding a common TCI to (1), which combines the
within- and across-trial interactions, results in
ln{H𝑗(t|xi𝑗)} = s𝑗 (ln(t)) + 𝛽1trt1i𝑗 + · · · + 𝛽qtrtqi𝑗 + 𝛼𝑗zi𝑗
+ 𝛿1trt1i𝑗zi𝑗 + · · · + 𝛿qtrtqi𝑗zi𝑗 ,
(3)
where the covariate zij is fitted as a fixed trial-level effect
with coefficient 𝛼j for trial j and 𝛿1, … , 𝛿q are the coeffi-
cients of the TCI effects.
In practice, these models can also be fitted with ran-
dom treatment effects (RTEs), random trial-level TCIs, and
random trial-level effect of the covariate (Appendix S1).
2.1.4 Missing covariate data
A NMA can be conducted in both the frequentist
and Bayesian frameworks.29,30 One of the advantages
of conducting NMA within a Bayesian framework, and
in particular using WinBUGS, is that missing covari-
ate data can be naturally handled in WinBUGS. Missing
covariate data can be accommodated within the NMA
model by including a distribution for the covariate
with missing values. This allows 2 things to happen:
Missing covariate values are imputed, which allows a
patient to be included in the NMA model, and this in
turn increases the precision of the treatment effects, which
themselves inform the imputation of the missing values.31
If we wish to perform a frequentist analysis, the most
straightforward way to handle missing covariate val-
ues is by multiple imputation; however, this is not
a straightforward application of multiple imputation,
because the imputation needs to be done in a way that is
consistent with the NMA model. The R-package jomo63
has the flexibility to handle this, but we do not pursue
this further.
2.2 Nine-step framework for 1-stage IPD
NMAwith treatment-covariate
interactions
The aim of this framework is to provide guidance on the
steps that need to be considered before a NMA with TCIs
can be fitted, so that the analysis is conducted system-
atically and appropriately. This framework concentrates
specifically on building NMAwith TCI models. Therefore,
the framework assumes that the usual MA activities such
as protocol writing, defining inclusion/exclusion crite-
ria, and determining whether trials are similar enough for
inclusion in a MA have already been conducted. Further,
we assume that the network is connected and any covari-
ates for inclusion in the NMAmodels have been identified
through discussion with clinicians. As usual, when inter-
preting the results, a range of possible causes of hetero-
geneity (eg, baseline differences, design, treatment doses,
delivery, and escape therapies)must be kept inmind. Steps
1 to 4 are applicable for any NMA whether covariates are
considered for inclusion or not. From step 5 onwards, the
framework specifically considers the inclusion of covari-
ates and TCIs. This framework has been developed to
be applicable to a range of outcomes (eg, binary, con-
tinuous, and time-to-event). As is common, we work on
the log-odds or log hazard scale. However, the principles
underlying our proposed framework will apply to other
settings, but the technical detailsmay vary. The framework
may need to be tweaked to take into account additional
issues arising in specific settings.
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1. Assess all pairwise treatment comparisons for evidence
of heterogeneity.
(a) If heterogeneity is present, explore the baseline
characteristics of all trials. Can the heterogeneity be
explained by differences in baseline characteristics
across trials?
(i) If yes, all important covariates should be con-
sidered going forwards.
(ii) If no, it could be unsuitable to combine the
pairwise comparison in a NMA.
2. Identify a reference treatment across the network and
determine which treatment contrasts will be param-
eterised in the model (all other treatment contrasts
should be obtained through consistency equations).
3. Fit the NMA model without covariates taking into
account any heterogeneity identified in step 1 (eg, by
using a random-effects model).
4. Assess the network for evidence of inconsistency.
5. Investigate patterns of missing data for the covariate of
interest.
6. Consider modelling assumptions for including the
covariate in the NMA model (FTE or RTE ? common,
fixed-trial, or random-trial effect of covariate?)
7. Fit NMA model including covariate and assess model
results.
8. Fit NMA model including TCIs with within- and
across-trial interactions separated and assess agree-
ment between the within- and across-trial interactions.
9. Fit NMA model including TCIs with within- and
across-trial interactions combined, if appropriate.
Note that when there are missing covariate data, it is
often practically and computationally easier to fit step 9
before step 8. More details can be found in Section 2.3.
2.3 Guidance on implementing
the framework
Step 1: Before a NMAmodel is fitted, all pairwise treat-
ment comparisons in the network should be explored
for evidence of heterogeneity. Heterogeneity can be
assessed through the I2, 𝜏2, andCochranQ statistics.32-34
If heterogeneity is present, explore the baseline char-
acteristics of all trials. If one trial, or a subgroup of
trials, is found to be causing the heterogeneity, then
exploring the baseline characteristics can identify what
is different about this trial, or trials, and the impact
this might have on the treatment effect. The iden-
tification of heterogeneity, at this stage, in one or
more pairwise comparisons can determine whether
FTE or RTE models are used in step 4.35 If the source
of heterogeneity cannot be identified or accounted
for, then either RTE will need to be used or it will
be unsuitable to use this comparison in a NMA, par-
ticularly if removing the pairwise comparison exhibit-
ing heterogeneity means that a FTE model can be
used. Any covariates identified, during this step, as
potentially causing heterogeneity should be considered
in steps 6 to 9.
Step 2: The previous standard of care, the largest treat-
ment node, and the treatment connected to the greatest
number of other treatments are the most appropriate
choices for the reference treatment within the net-
work. The treatment parameterisation of the network
should satisfy the consistency equations.36 The num-
ber of treatment parameters should be one less than
the number of treatments in the network. The network
diagram can help inform which treatment parameters
should be directly estimated in the NMA model and
which will be calculated as contrasts through the con-
sistency equations. Network diagrams can be created in
Stata37 using the networkplot command.38
Step 3: A NMA model can be fitted using both FTE
and RTE and monitoring the deviance information cri-
teria (DIC). If heterogeneity was present in step 2, the
RTE model should be used as this increases the vari-
ability around the point estimate to reflect the hetero-
geneity. The RTE model gives more weight to smaller
studies than the FTE model does. Therefore, a dif-
ference in the treatment effect estimates between the
FTE and RTEmodels can indicate publication bias and
small study effects.27The DIC is a measure of model
fit, which penalises model complexity—smaller values
are better. The DIC can be used to compare mod-
els, although small differences (ie, <5) should not be
overinterpreted and simpler models should be chosen
where they can be.39 In addition, in some cases, total
residual deviance can be used to assess goodness of fit;
see Dias et al18 for details.
Step 4: The network should be assessed for evi-
dence of inconsistency.5,21,40-44 To visualise this, it is
useful to present the model results as a forest plot
with the network, direct, and indirect evidence sep-
arated out. There are many approaches to assess-
ing inconsistency (eg, node-splitting,45-47 inconsistency
models such as the design-by-treatment interaction
model,48,49 random inconsistency effects,50-52 factorial
analysis of variance,53 generalised linear mixed mod-
els,54,55 and the 2-stage approach56). We recommend
consulting review papers such as Donegan et al20
and Efthimiou et al,57 which describe and compare
different methods for assessing consistency to help
select the most appropriate method for the network
at hand.
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We use the inconsistency parameter approach of Lu
and Ades42 in which an inconsistency parameter is
fitted for each treatment loop and the model is refit-
ted including the additional parameters. This approach
complements the assessment of heterogeneity from
step 1 and follows the approach outlined in Freeman
and Carpenter.28 Here, an inconsistency parameter is
initially added to the FTEmodel before considering the
RTE model and exploring whether the conclusions are
sensitive to the inclusion of the inconsistency parame-
ter. If inconsistency is present in the network, then an
inconsistency parameter can be used in all furthermod-
els. Treatment loops with inconsistency parameters are
reduced to the direct evidence only and therefore do
not contribute to the across-trial interaction in the
network. Furthermore, if inconsistency is present, the
cause of the underlying inconsistency/heterogeneity
must be resolved before the results are used for clinical
inference.22,28
Step 5: Consider the distribution of the covariate of
interest in each trial. Are there any trials where some
patients have missing covariate data? Are there any
trials where all patients have missing covariate data?
Is the covariate continuous or categorical? Can a lin-
ear effect between the groups of an ordered categori-
cal covariate be assumed? What is the reference value
of the covariate? In WinBUGS,58 as in all Bayesian
modelling software, missing covariate data can be
imputed once themarginal distribution of the covariate
is specified.
Step 6: Covariates can be included as common effects,
fixed trial-level effects, or random trial-level effects.
The DIC can be used to determine which of these
assumptions is most appropriate. However, assuming
a common effect of a covariate is only likely to be
appropriate if the distribution of the covariate is the
same in every trial in the network. The choice of FTE
or RTE should be informed by previous steps such as
the presence of heterogeneity from step 2 or the DIC
from step 4.
Step 7: Fit the NMAmodels including the patient-level
covariate and assess the results. This can help inform
the decision of which NMA model with TCI to fit.
TCIs can be fitted as common effects, fixed trial-level
effects, or random trial-level effects. A common effect
assumes that the TCI has the same effect in all trials.
A random trial-level effect allows the effect of the TCI
to differ in each trial but assumes that the coefficients
for each trial come from a common (typically normal)
distribution. The choice of assumption for TCIs can be
informed by the distribution of the covariatewithin and
across trials.
Steps 8 and 9: The framework recommends that the
within- and across-trial interactions are considered sep-
arately at first and then combined if it is appropri-
ate to do so. However, the mean covariate value from
each trial is needed to separate out the within- and
across-trial interactions and to calculate this missing
covariate data needs to be imputed. Although it is pos-
sible, in principle, to impute themissing covariate data,
calculate the mean covariate value, and fit the NMA
model separating within- and across-trial interactions
in one step, in practice, software is unlikely to do
this. Therefore, it is more practical and computation-
ally easier to fit the model combining within- and
across-trial interactions first and monitor the mean
value of the covariate in any trials with missing covari-
ate data before using these values to fit the model
separating the within- and across-trial interactions.
For trials with only some missing covariate data, the
weighted average of themean observed value andmean
imputed value of the covariate can be used as the trial
mean value. In trials where all patients have missing
covariate values, the mean covariate value from the
imputed values can be used as the trial mean value.
A sensitivity analysis in which patients with missing
covariate data are excluded can be conducted to check
that the imputation of the missing covariate data has
been handled correctly.
A visual assessment of the agreement between the
within- and across-trial interactions can be made by
plotting the parameter estimates for the TCIs. Log haz-
ard ratios (LogHR) along with 95% credible intervals
(CrI) can be presented in tables. If TCIs are present,
the treatment effect parameters on their own do not
have a useful interpretation. Treatment effects should
be presented separately for each level of the covari-
ate. Consistency can then be checked for each level of
the covariate following methods described by Donegan
et al.22 Graphs ranking the treatments for each level of
the covariate can be used as a visual aid for determin-
ing the most effective treatment for each level of the
covariate.38,59
2.4 Example
Our example comes from 3 MAs of randomised con-
trolled trials (RCTs) in cervical cancer performed by
2 international collaborations.60,61 The 3 MAs considered
4 different treatments: radiotherapy (RT), chemoradiation
(CTRT), neoadjuvant chemotherapy plus radiotherapy
(CT+RT), and neoadjuvant chemotherapy plus surgery
(CT+S) (Figure 1).
The RT vs CTRT comparison included a total of 18 RCTs
and 4818 patients. In the original publication, 5 of these
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FIGURE 1 Cervical cancer network diagram. Node size is
proportional to the number of patients randomised to each
treatment, and line thickness is proportional to the number of
studies involved in each direct comparison. Note that this network
diagram includes the main set of 13 RT vs CTRT trials only (which
in this paper is analysed as 16 trials owing to the splitting of 3
four-arm trials each into 2 unconfounded comparisons of RT vs
CTRT), and the number of patients for each treatment arm does not
add up to the total number of patients included in the network,
because multiarm patients are counted twice. There are a total of 37
trials in this network. However, in the figure, the 2 multiarm trials
are counted 3 times each as they are included in the number of
trials for each pairwise comparison. CT+RT indicates neoadjuvant
chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy
plus surgery; CTRT, chemoradiation; RT, radiotherapy
trials were only included in sensitivity analyses as patients
on at least one of the treatment arms received additional
treatment. This resulted in a subset of 13 trials (3104
patients), which were identified and used for the primary
analysis. Within this subset of 13 trials, 1 three-arm trial
combined 2 different forms of CTRT and compared them
with a single control arm and 3 four-arm trials were split
into 2 unconfounded comparisons of RT vs CTRT for anal-
ysis as separate trials. This resulted in 16 trials included in
the primary analysis. In this paper, we will only consider
the trials used in the primary analysis and will treat the
data in the same way as the original publication.60
Across the 3MAs that form our network of trials, overall
survival datawere available for 5922 patients from 37RCTs
(35 two-arm RCTs and 2 three-arm RCTs). Covariate data
were available for stage of disease from 5517 patients from
36 RCTs.
3 RESULTS
3.1 Application of framework to cervical
cancer network
In this section,we illustrate the application of the proposed
framework for 1-stage IPD NMA with TCIs to the cervical
cancer network. In this example, we use the 1-stage IPD
Royston-Parmar NMA model in the Bayesian setting to
analyse overall survival.28 On the basis of the availability
of IPD, stage of disease will be considered for inclusion in
a NMA model with TCIs. With a test of linearity, we treat
stage of disease as linear throughout the rest of this paper.
All models were fitted inWinBUGS58 version 1.4.3 and run
with 20 000 burn-in and 20 000 iterations and 2 sets of
initial values. Convergence was checked by examining the
trace and histograms of the posterior distribution. Models
were compared using the DIC statistic.31,39 Parameters rep-
resenting the spline function for the baseline log cumula-
tive hazard function, treatment effects, and inconsistency
parameters were fitted with noninformative normal prior
distributions. In the RTEmodel, the treatment effects were
modelled using a multivariate normal distribution with
the mean coming from a normal distribution and preci-
sion from a Wishart distribution. Parameter estimates are
presented as LogHR and 95% CrI for the posterior mean.
A LogHR of 0 indicates a null effect, and a LogHR less
than 0 indicates a beneficial effect relative to the reference
treatment, RT.
Step 1: All pairwise treatment comparisons were
assessed for evidence of heterogeneity using the
Cochran Q statistic and the I2 statistic.32,33 There
was no evidence of heterogeneity within the RT vs
CTRT (P = .625, Table 1) and CT+RT vs CT+S
(P = .939) comparisons while there was some evi-
dence of statistical heterogeneity in the RT vs CT+S
(P = .065) comparison and substantial heterogene-
ity in the RT vs CT+RT comparison (P < .001,
also noted in the original publication61). The base-
line characteristics of all trials were compared. A pre-
specified analysis of RT vs CT+RT identified a differ-
ence in treatment effect by chemotherapy cycle length.
Therefore, CT+RT was split into 2 treatments on the
basis of the length of chemotherapy cycles. Through-
out the rest of this paper, trials with chemotherapy
cycles less than or equal to 14 days will be referred to
as “short cycles” and trials with chemotherapy cycles
greater than 14 days will be referred to as “long
cycles.” No evidence of heterogeneity was found in the
RT vs CT+RT long cycles comparison (P = .263).
However, there was evidence of heterogeneity in the
RT vs CT+RT short cycles comparison (P = .002).
Heterogeneity can also be assessed visually from the
forest plots in Figure 2. Treatment effects are presented
in Table 1.
We also assessed the assumption of proportional haz-
ards (PH). Following the methods described by Free-
man and Carpenter,28 we performed a global test of
nonproportionality, which was not significant for any
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TABLE 1 Cervical cancer meta-analysis results using Royston-Parmar models
Comparison FTEa Cochran Q Global Non-PH Test
RT vs CTRT −0.215 12.71, 15 df, 𝜒2 = 0.161, 1 df,
(−0.336, −0.086) P = .625 P = .688
RT vs CT+RT short cycles −0.191 20.69, 6 df, 𝜒2 = 2.522, 1 df,
(−0.375, −0.007) P = .002 P = .112
RT vs CT+RT long cycles 0.227 12.34, 10 df, 𝜒2 = 0.006, 1 df,
(0.073, 0.385) P = .263 P = .944
RT vs CT+S −0.447 8.85, 4 df, 𝜒2 = 0.118, 1 df,
(−0.654, −0.243) P = .065 P = .731
CT+RT vs CT+S −0.444 0.01, 1 df, 𝜒2 = 0.164, 1 df,
(−0.830, −0.061) P = .939 P = .686
Abbreviations: CT+RT, neoadjuvant chemotherapy plus radiotherapy; CT+S, neoadjuvant
chemotherapy plus surgery; CTRT, chemoradiation; FTE, fixed treatment effect; PH, proportional
hazards; RT, radiotherapy.
aValues are log hazard ratios and 95% credible intervals.
FIGURE 2 Cervical cancer meta-analysis plots. Trial results come from a fixed treatment effect Royston-Parmar model. Overall results
come from a 1-stage IPD fixed treatment effect Royston-Parmar MA model. Top left: RT vs CTRT. Top right: RT vs CT+RT. Bottom left: RT vs
CT+S. Bottom right: CT+RT vs CT+S. CrI indicates credible interval; CT+RT, neoadjuvant chemotherapy plus radiotherapy; CT+S,
neoadjuvant chemotherapy plus surgery; CTRT, chemoradiation; LogHR, log hazard ratio; MA, meta-analysis; RT, radiotherapy [Colour
figure can be viewed at wileyonlinelibrary.com]
of the pairwise comparisons; therefore, we continue
under the assumption of PH in the cervical cancer
network.
Step 2: RT was chosen as the reference treatment
because it was the previous standard of care. We
included the RT vs CTRT, RT vs CT+RT, and RT
vs CT+S treatment contrasts as parameters in the NMA
model resulting in the treatment effect for CT+RT
vs CT+S being estimated through the consistency
equation.
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Step 3:A 1-stage IPDRoyston-Parmar NMAmodel was
fitted to the cervical cancer network using both FTE
and RTE with the results presented in Table 2. The
DIC provides only weak evidence in favour of the RTE
model (FTE DIC = 12 321.5, RTE DIC = 12 315.8).
However, owing to the presence of heterogeneity in
the RT vs CT+S short cycles comparison, identified
in step 1, the RTE model was deemed to be the most
appropriate model.
Step 4: In Figure 3, the direct and indirect treatment
effects differ from each other with the network esti-
mates balancing out these 2 sources of information.
The direct and indirect treatment effects are estimated
through the inclusion of an inconsistency parame-
ter, which was estimated as −0.484 (95% CrI: −1.314,
0.354). The Cochran Q statistic showed some evidence
of inconsistency between designs (Q = 10.32, 2 df,
P = .006). The inconsistency between designs is driven
by one trial,62 which had a treatment effect estimate
more extreme than that of the other trials.
In addition, we also assessed globally the assumption of
PHacross the network using themethod recommended
by Freeman and Carpenter.28 TheWald test for non-PH
from the RTE model with random treatment-ln(time)
interactions gave 𝜒2 = 0.324 on 3 df(P = .955) giving
no evidence of non-PH within the network.
Step 5: A linear effect of stage of disease was
assumed, which could take the values 0 = stages IA
to IIA, 1 = stage IIB, and 2 = stages IIIA to IVA.
We assessed this assumption by conducting a Wald
test for each trial, which included patients covering all
3 categories of stage of disease. As each trial is indepen-
dent, we summed together the chi-squared statistics to
provide an overall test of the linearity assumption. This
gave 𝜒2 = 8.19 on 12 df and P = .77. Therefore, we pro-
ceeded with the assumption of a linear effect for stage
of disease.
Thirteen trials had at least one patient with missing
stage data. One of these trials had missing stage data
for all patients. To impute values ofmissing stage of dis-
ease (whether explicitly, using multiple imputation, or
as part of a Bayesianmodel), we need to assume a distri-
bution.Weused a truncated normal distribution,which
we believe is a reasonable approximation for a clin-
ical severity measure of this kind. This is especially
so as (in common with other settings) the majority of
TABLE 2 Posterior mean and 95% credible intervals for treatment effects from NMAmodels
Treatments FTE RTE RTE + Stagea
CTRT −0.211 (−0.337, −0.087) −0.207 (−0.374, −0.046) −0.198 (−0.346, −0.031)
CT+RT short cycles 0.028 (−0.164, 0.220) 0.086 (−0.229, 0.428) 0.005 (−0.320, 0.328)
CT+RT long cycles 0.223 (0.065, 0.380) 0.273 (0.031, 0.538) 0.254 (0.008, 0.540)
CT+S −0.396 (−0.611, −0.185) −0.333 (−0.701, 0.011) −0.372 (−0.803, 0.056)
Stage 0.561 (0.475, 0.641)
Abbreviations: CT+RT, neoadjuvant chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy plus surgery;
CTRT, chemoradiation; FTE, fixed treatment effect; NMA, network meta-analysis; RT, radiotherapy; RTE, random
treatment effect.
aStage is fitted as a random trial-level effect.
FIGURE 3 NMA results for the cervical cancer network. Left: Fixed treatment effect. Right: Random treatment effect. CT+RT indicates
neoadjuvant chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy plus surgery; CTRT, chemoradiation; NMA, network
meta-analysis; RT, radiotherapy
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information is recovered by bringing the observed data
on patients with missing stage into the model, and not
on the stage coefficients themselves. In WinBUGS, the
normal distribution was truncated through the use of
the “I” function to restrict missing covariates to take
values between 0 and 2. Results with a categorical stage
model were similar, but we found it harder to obtain
convergence.
Step 6: A common effect of stage of disease appeared
to be inappropriate as the distribution of stage of dis-
ease varies across trials and the network includes trials
of varying sizes. In addition, the DIC showed that a ran-
dom effect of stage was most appropriate. Therefore,
an RTE model with random trial-level effect of stage of
disease was fitted.
Step 7: As expected, when included as a covariate, the
parameter estimate for stage of disease suggests that
overall survival is reduced as stage of disease increases
(LogHR = 0.561, 95% CrI: 0.475, 0.641; Table 2).
Despite the inclusion of stage of disease as a covari-
ate, the treatment effect for CTRT compared with RT
remained statistically significant.
Step 8: A RTE model with fixed trial-level effect
of stage of disease and random trial-level effect of
treatment-stage interactions separating out the within-
and across-trial interactions was fitted. There were no
statistically significant interactions between treatment
and stage of disease (Table 3). The CrI for the RT
vs CT+S comparison are much wider, relative to the
other treatment comparisons, possibly reflecting the
small amount of within-trial interaction. In this com-
parison, there are only 2 trials that have patients dis-
tributed over more than one value of stage and can
therefore contribute to the within-trial interaction.
A visual assessment of the consistency of the within-
and across-trial interactions was conducted by plotting
the parameter estimates for the treatment-stage inter-
actions (Figure 4). To determine whether any infor-
mation was gained from the NMA, we also plotted
the MA estimates from a FTE model (Figure 4). We
used a relatively strict criterion considering agreement
to be shown if the within-trial interaction was within
half a standard error of the across-trial interaction.
For the RT vs CTRT comparison, there is agreement
between the within- and across-trial interactions. This
is in line with our expectations as the RT vs CTRT
comparison was a branch of the network without any
indirect evidence informing the comparison. However,
in the case of RT vs CT+RT and RT vs CT+S, the
within- and across-trial interactions do not agree. For
example, the LogHR of the within-trial interaction
for CT+RT is −0.035 (95% CrI: −0.285, 0.204) and
the LogHR for the across-trial interaction is 0.110
(95% CrI: −0.315, 0.545; Table 3). The within- and
across-trial interactions are not consistent with each
other, and the across-trial interaction could be sub-
ject to ecological bias. Therefore, we should focus on
the within-trial interaction only. For the RT vs CT+RT
and RT vs CT+S comparisons, further investiga-
tion into the difference between the within- and
across-trial interactions may be required as these com-
parisons could be subject to ecological bias.
TABLE 3 Posterior mean and 95% credible intervals for treatment and treatment-stage interaction
effects from NMAmodels including treatment-stage interactions with within- and across-trial
interactions separated and combineda
Within- and Across-trial Within- and Across-trial
Treatments Interactions Separated Interactions Combined
RT vs CTRT −0.421 (−0.910, 0.101) −0.428 (−0.738, −0.114)
RT vs CT+RT short cycles −0.007 (−0.519, 0.550) 0.118 (−0.273, 0.596)
RT vs CT+RT long cycles 0.100 (−0.551, 0.670) 0.099 (−0.426, 0.613)
RT vs CT+S 0.332 (−0.593, 1.102) −0.195 (−0.855, 0.380)
RT vs CTRT—stage within 0.176 (−0.069, 0.417)
RT vs CT+RT—stage within −0.035 (−0.285, 0.204)
RT vs CT+S—stage within 0.172 (−0.459, 0.776)
RT vs CTRT—stage across 0.165 (−0.279, 0.584)
RT vs CT+RT—stage across 0.110 (−0.315, 0.545)
RT vs CT+S—stage across −0.563 (−1.319, 0.230)
RT vs CTRT—stage combined 0.170 (−0.043, 0.373)
RT vs CT+RT—stage combined 0.006 (−0.234, 0.212)
RT vs CT+S—stage combined −0.120 (−0.635, 0.415)
Abbreviations: CT+RT, neodadjuavnt chemotherapy plus radiotherapy; CT+S, neoadjuvant chemotherapy plus
surgery; NMA, network meta-analysis; RT, radiotherapy.
aReference level is stages IA to IIA.
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FIGURE 4 Treatment-stage interaction parameter estimates.
Top: RT vs CTRT. Middle: RT vs CT+RT. Bottom: RT vs CT+S. Solid
lines represent NMA estimates. Dashed lines represent pairwise
MA estimates. CT+RT indicates neoadjuvant chemotherapy plus
radiotherapy; CT+S, neoadjuvant chemotherapy plus surgery;
CTRT, chemoradiation; FTE, fixed treatment effect; MA,
meta-analysis; NMA, network meta-analysis; RT, radiotherapy;
RTE, random treatment effect
Step 9: To fully illustrate our framework, we also
fitted a model combining the within- and across-
trial interactions (Table 3). However, as mentioned in
step 8, the within- and across-trial interactions should
remain separated. Additionally, a sensitivity analysis
in which patients with missing stage of disease were
excluded was conducted (Table S2.1). Tables 3 and S2.1
show good agreement between the 2 models. However,
in Table S2.1, the across-trial interaction from theCT+S
and stage interaction was statistically significant.
4 DISCUSSION
NMA with TCIs has the potential to identify groups of
patients most likely to respond to treatment. We have
proposed a practical framework that aims to encourage
researchers to conduct 1-stage IPD NMA with TCIs in a
systematic and appropriate manner. We have successfully
applied the framework to a cervical cancer network. The
framework highlights the importance of preliminary anal-
yses to consider issues such as heterogeneity and incon-
sistency, which may inform decisions around the most
appropriate modelling assumptions. This framework is
deliberately generic, so that it can be applied to a range of
outcomes (eg, binary, continuous, and time-to-event) and
has the potential to improve the conduct and analysis of
NMA with TCIs.
In the cervical cancer network, we showed that stage of
disease had a statistically significant effect on overall sur-
vival with advanced disease increasing the risk of death.
Owing to the presence of heterogeneity in the network,
a RTE model was considered to be the most appropri-
ate. There was no evidence of a treatment-stage interac-
tion on the basis of the within-trial interaction for any
of the treatments leading to the conclusion that stage
of disease did not modify the treatment effect. On the
basis of our relatively strict criterion, the treatment-stage
interaction models showed a difference between the
within- and across-trial interactions for some of the
comparisons, and it was thereforemost appropriate to sep-
arate out the within- and across-trial interactions. The
small difference in the NMA and MA estimates of the
across-trial interaction suggested that some across-trial
interactions might have been gained from the network.
Our criterion for assessing agreement between the within-
and across-trial interactions is arguably somewhat strict
and arbitrary. However, we feel it is better to be cau-
tious as a number of TCIs identified in the literature have
subsequently been debunked.6
The cervical cancer network is a small, well-connected
network with a lot of direct evidence. Despite this, we
were still able to show that some across-trial interaction
is gained when conducting a NMA. Information (in the
statistical sense of the inverse of the squared standard
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error) is gained in a NMA when the direct evidence and
indirect evidence are consistent. In practice, not all net-
works will contain as much direct evidence as the cervi-
cal cancer network. Therefore, we would expect NMA to
contribute a greater amount of statistical information on
an across-trial interaction in a consistent network where
some treatment comparisons are only informed by a small
amount of direct evidence. We may also expect to gain
more information when using a fixed-effects NMA.
A reviewer suggested that (as the IPD data are avail-
able) the following simpler analysis may be preferable:
(1) perform a 2-stage MA of the within-study interaction
effects and then (2) derive the interaction effects within
each study using the IPD and then performNMAon these.
In applications, this could provide a useful cross-check
of the results. However, in our setting, the network gives
us the best treatment estimates against which to estimate
an interaction. Further, NMA goes beyond just estimat-
ing treatment and interaction effects: A key motivation for
NMA is to rank treatments in terms of efficacy. The inclu-
sion of TCIs allows us to consider whether the ranking
of treatments varies by covariate level. Indeed, if a TCI is
present, we should rank treatments for each level of the
covariate.
With the cervical cancer network, we did not need to
include an inconsistency parameter. However, in a net-
work with one treatment loop, if an inconsistency param-
eter is included, then it may also be appropriate to allow
for inconsistency in the TCIs. This would be equivalent to
conducting separate pairwise MA with TCI, and nothing
would be gained from conducting a NMA. We also only
considered one covariate, whereas in practice, researchers
may wish to consider multiple covariates. In this case,
we would recommend considering each covariate on its
own initially before combining any covariates identified as
being clinically important within a NMAmodel.
By definition, NMA uses both the within- and
across-trial interactions. Using the across-trial interaction
requires the assumption of no unmeasured confound-
ing, but unfortunately, this assumption will always
be hard to test. Making this assumption allows infor-
mation to be gained from the network to inform
both treatment effect estimates and TCIs. Each trial
contributes to the within-trial interaction, which is esti-
mated using patient-level covariates. Meanwhile, the
across-trial interaction is estimated through the relation
of the trial-level aggregated covariates.13 Although com-
bining within- and across-trial interactions can result in
greater power to detect TCIs, the across-trial interaction
can introduce ecological bias.3 It is therefore important
that the within- and across-trial interactions for TCIs
can be separated out.6 Separating out the within- and
across-trial interactions allows the influence of the
across-trial interaction on the TCI to be assessed and
allows researchers to identify which data source is driving
the TCI.
5 CONCLUSION
NMA with TCIs has the potential to identify
groups of patients most likely to respond to treat-
ment. To do this, NMA requires the use of both
within- and across-trial interactions. However, the
across-trial interaction can be subject to ecological
bias. Therefore, it is important that the within- and
across-trial interactions in a NMA can be separated
and checked for agreement. We have shown that
NMA models can be parameterised to separate out
the within- and across-trial interactions. Our proposed
framework incorporates the separation of within- and
across-trial interactions, can be applied to any outcome,
outlines the steps to conducting NMA with TCIs in
a systematic manner, provides practical guidance for
researchers, and reduces the risk of unduly optimistic
interpretation of TCIs.
HIGHLIGHTS
What is already known?
• Treatment-covariate interactions explore how a treat-
ment effect varies in relation to a patient-level covariate.
• Treatment-covariate interactions contain within- and
across-trial interactions, where the across-trial
interaction is susceptible to confounding and ecological
bias.
What is new?
• We propose a 9-step framework for IPD NMA with
TCIs.
• Weuse a cervical cancer example to show how to imple-
ment the framework, parameterise the NMA models
to separate out the within- and across-trial interac-
tions, and assess the consistency of the within- and
across-trial interactions.
Potential impact for Research SynthesisMethods readers
outside the authors' field:
• This framework provides practical guidance for
researchers outlining the steps for conducting NMA
with TCIs in a systematic manner, reducing the risk of
overly optimistic interpretation of TCIs.
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